VarunVijay KumarMongaMD

Clinical Trials

• Gemcitabine Plus Ascorbate for Sarcoma in Adults Start of enrollment: 2018 Jul 11

  Terminated

  Phase 2

• High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas Start of enrollment: 2019 Jun 27

  Active, not recruiting

  Phase 1, Phase 2

• Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial Start of enrollment: 2017 Jul 18

  Active, not recruiting

  Phase 1

  Roles: Sponsor-Investigator, Principal Investigator, Contact

• Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma Start of enrollment: 2023 Apr 01

  Withdrawn

  Not Applicable

  Roles: Sponsor-Investigator, Contact, Principal Investigator

• TVEC and Preop Radiation for Sarcoma (8 ml Dose) Start of enrollment: 2020 Sep 10

  Active, not recruiting

  Phase 1, Phase 2

  Roles: Contact, Principal Investigator, Sponsor-Investigator

• PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Start of enrollment: 2015 Nov 04

  Active, not recruiting

  Phase 1, Phase 2

  Roles: Principal Investigator, Contact

• Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration Start of enrollment: 2019 Oct 07

  Recruiting

  Phase 2

  Roles: Contact

• A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations Start of enrollment: 2021 Feb 28

  Active, not recruiting

  Phase 1

  Roles: Principal Investigator, Contact

• A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations Start of enrollment: 2021 Feb 28

  Active, not recruiting

  Phase 1

  Roles: Principal Investigator, Contact

• Chlorpromazine and Standard of Care in Glioblastoma Start of enrollment: 2022 Jan 28

  Active, not recruiting

  Phase 1

  Roles: Contact, Principal Investigator, Sponsor-Investigator

• Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot) Start of enrollment: 2020 Nov 24

  Recruiting

  Early Phase 1

  Roles: Sponsor-Investigator, Contact, Principal Investigator

• Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 2020 Jan 14

  Active, not recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• Join now to see all